Umlaut.bio is developing small molecules that target transfer RNA modifications for cancer and inflammatory diseases. The entry of BaseLaunch brings its pre-seed round to around EUR 3 million to advance its work.
- Announced on
- Round
- Pre-seed
- Amount
- EUR 3 M
- Location
- canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- BaseLaunch
- High-Tech Gründerfonds
- LBBW Venture Capital
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic